{'52WeekChange': 1.3006835,
 'SandP52WeekChange': 0.0644362,
 'address1': '201 Elliott Avenue West',
 'address2': 'Suite 230',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 10.69,
 'askSize': 1000,
 'averageDailyVolume10Day': 133987,
 'averageVolume': 827811,
 'averageVolume10days': 133987,
 'beta': 1.884615,
 'beta3Year': None,
 'bid': 10.02,
 'bidSize': 1000,
 'bookValue': 1.337,
 'category': None,
 'circulatingSupply': None,
 'city': 'Seattle',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 10.9,
 'dayLow': 9.8,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.805,
 'enterpriseToRevenue': 61.35,
 'enterpriseValue': 173681712,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 8.459143,
 'fiftyTwoWeekHigh': 15,
 'fiftyTwoWeekLow': 2.05,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 3901041,
 'forwardEps': -0.22,
 'forwardPE': -45.909092,
 'fromCurrency': None,
 'fullTimeEmployees': 53,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.4052,
 'heldPercentInstitutions': 0.44393003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1500940800,
 'lastSplitFactor': '1:4',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/alpineimmunesciences.com',
 'longBusinessSummary': 'Alpine Immune Sciences, Inc. focuses on the discovery '
                        'and development of protein-based immunotherapies for '
                        'the treatment of cancer, autoimmune/inflammatory '
                        'disorders, and other diseases. Its lead programs '
                        'include ALPN-101, an inducible T cell costimulator '
                        '(ICOS)/cluster of differentiation 28 (CD28) '
                        'antagonist program for the treatment of autoimmune '
                        'and inflammatory diseases; and ALPN-202, a programmed '
                        'cell death protein ligand 1 (PD-L1)/cytotoxic '
                        'T-lymphocyte associated protein 4 (CTLA-4) antagonist '
                        'with PD-L1 dependent CD28 costimulation for the '
                        'treatment of cancer. The company has a collaboration '
                        'and licensing agreement with the Kite Pharma, Inc. '
                        'for discovering and developing protein-based '
                        'immunotherapies targeting the immune synapse to treat '
                        'cancer. Alpine Immune Sciences, Inc. is headquartered '
                        'in Seattle, Washington.',
 'longName': 'Alpine Immune Sciences, Inc.',
 'market': 'us_market',
 'marketCap': 187737792,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_283828497',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -35004000,
 'nextFiscalYearEnd': 1640908800,
 'open': 10.9,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '206-788-4545',
 'previousClose': 10.08,
 'priceHint': 2,
 'priceToBook': 7.554226,
 'priceToSalesTrailing12Months': 66.31501,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 10.9,
 'regularMarketDayLow': 9.8,
 'regularMarketOpen': 10.9,
 'regularMarketPreviousClose': 10.08,
 'regularMarketPrice': 10.9,
 'regularMarketVolume': 218545,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 18587900,
 'sharesPercentSharesOut': 0.0023999999,
 'sharesShort': 45190,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6254,
 'shortName': 'Alpine Immune Sciences, Inc.',
 'shortPercentOfFloat': 0.0089,
 'shortRatio': 0.02,
 'startDate': None,
 'state': 'WA',
 'strikePrice': None,
 'symbol': 'ALPN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.883,
 'twoHundredDayAverage': 4.4715466,
 'volume': 218545,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.alpineimmunesciences.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '98119'}